CHEK2

Germline Mutations As Prognostic Indicators of Castrate Resistance

In summary, these results demonstrate worse outcomes in men with germline BRCA2 and CHEK2 mutations compared with men without these mutations when treated with standard first-line ADT with LHRH analogs.